A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma
Authors:
Open Access
- 15 September 2016
- journal article
- review article
- Published by Taylor & Francis in CNS Oncology
- Vol. 6 (1) , 29-43
Abstract
Tumor treating fields (TTFields) are an integral treatment modality in the management of glioblastoma and extend overall survival when combined with maintenance temozolomide in newly diagnosed patients. Complexities exist regarding correct selection of imaging sequences with which to perform TTFields treatment planning. Guidelines are warranted first, to facilitate treatment planning standardization across medical disciplines and institutions, to ensure optimal TTFields delivery to the tumor and peritumoral brain zone while maximizing patient safety, and also to mitigate the risk of premature cessation of a potentially beneficial treatment. This summary guideline outlines methods for starting patients on TTFields, for monitoring patient response to therapy and provides a framework for evaluating when therapy should be re-planned, based on the extent of sequential imaging changes.Keywords
Funding Information
- ERC Belgium
This publication has 51 references indexed in Scilit:
- A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancerLung Cancer, 2013
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaNew England Journal of Medicine, 2013
- Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imagingActa Radiologica, 2013
- The incidence and significance of multiple lesions in glioblastomaJournal of Neuro-Oncology, 2013
- Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-l-tyrosine PET in comparison to MRIEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modalityEuropean Journal of Cancer, 2012
- Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteriaNeuro-Oncology, 2012
- Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment GliomaAmerican Journal of Neuroradiology, 2011
- Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungsClinical & Experimental Metastasis, 2009
- Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumorsProceedings of the National Academy of Sciences, 2007